Inactive

Request for Information (RFI) Instructions Background: This Sources Sought Request for Information (RFI) is for information, planning and market research purposes only and shall not be construed as ei... Request for Information (RFI) Instructions Background: This Sources Sought Request for Information (RFI) is for information, planning and market research purposes only and shall not be construed as either a solicitation or obligation on the part of the Food and Drug Administration or its Centers. The purpose of this RFI is to help the FDA identify potential Atlas Licenses and Maintenance providers and their small business size standard. FDA will use this market research information to assess the market's capability to successfully meet FDA's mission. FDA welcomes responses from all interested businesses. FDA does not intend to make a selection decision or award a contract on the basis of responses nor otherwise pay for the preparation of any information submitted or FDA's use of such information. Acknowledgment of receipt of responses will not be made, no questions will be answered, nor will respondents be notified of the outcome of the FDA's review of the information received. The result of this RFI does not mean the Government will be issuing a solicitation or that there is a requirement for purchase. Additionally, the FDA does not intend to hold discussions concerning this RFI with any interested parties. However, FDA reserves the right to contact vendors if additional information is required. General Instructions: A complete response to the RFI should include answers to all of the questions below. Please note that a respondent's failure to provide a complete response to a question will be interpreted to mean that it does not understand the question and does not demonstrate the capability to provide services required. Responses should demonstrate capability, not merely affirm the respondent's capability (e.g.: The response must go beyond the statement that, "XYZ company can provide training support."). The RFI responses should be submitted via email to Steven Chang at Tzeleong.Chang@fda.hhs.gov by 12:00 noon on July 30, 2020. E-Mail is the only acceptable method of delivery for this sources sought notice.